Top-News

Cambiar Aggressive Value ETF News

ETF
WKN:  ISIN:  US0075W01639 US-Symbol:  CAMX
27,154 €
+0,00 $
0,00%
27,154 € 27.10.25
Depot/Watchlist
Indexbildung
Ertragsverwendung
Thesaurierend
Lfd. Kosten
-
Fondsgröße
-  
Tracking Error
-
Währung
FWW Fundstars
keine Bewertung

Cambiar Aggressive Value ETF News

10.11.25 - PR Newswire
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
Camurus reports positive topline results for CAM2056, semaglutide monthly depot PR Newswire
10.11.25 - PR Newswire
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
Camurus reports positive topline results for CAM2056, semaglutide monthly depot PR Newswire
28.08.25 - PR Newswire
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK
Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK PR Newswire
01.07.25 - PR Newswire
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU PR Newswire
01.07.25 - PR Newswire
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU PR Newswire
18.06.25 - PR Newswire
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients PR Newswire
18.06.25 - PR Newswire
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients PR Newswire
03.06.25 - PR Newswire
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Camurus and Lilly enter collaboration and license agreement for long-​acting FluidCrystal® incretins PR Newswire
03.06.25 - PR Newswire
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Camurus and Lilly enter collaboration and license agreement for long-​acting FluidCrystal® incretins PR Newswire
25.04.25 - PR Newswire
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU PR Newswire
25.04.25 - PR Newswire
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU PR Newswire

Newssuche

Videos

newspaper
08.12.25 +5,61%
Technical Trading: Die besten 3 Tage
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »